about
Biomaterial Approaches to Enhancing Neurorestoration after Spinal Cord Injury: Strategies for Overcoming Inherent Biological ObstaclesThe Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) ProdrugsDesign and cellular studies of a carbon nanotube-based delivery system for a hybrid platinum-acridine anticancer agentLipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Triptolide suppresses the in vitro and in vivo growth of lung cancer cells by targeting hyaluronan-CD44/RHAMM signaling.Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer.Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: A synergistic combination nanotherapy for ovarian cancer treatment.Polymer micro- and nanocapsules as biological carriers with multifunctional properties.Release kinetics of paclitaxel and cisplatin from two and three layered gold nanoparticles.A new approach to reduce toxicities and to improve bioavailabilities of platinum-containing anti-cancer nanodrugs.EGFR Targeted Theranostic Nanoemulsion for Image-Guided Ovarian Cancer Therapy.Transportan 10 improves the anticancer activity of cisplatin.Design of a novel theranostic nanomedicine: synthesis and physicochemical properties of a biocompatible polyphosphazene-platinum(II) conjugate.Encapsulation of lipophilic kiteplatin Pt(iv) prodrugs in PLGA-PEG micelles.Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines.Controlled-release systems for metal-based nanomedicine: encapsulated/self-assembled nanoparticles of anticancer gold(III)/platinum(II) complexes and antimicrobial silver nanoparticles.Non-covalent and reversible functionalization of carbon nanotubesDriving forces for drug loading in drug carriers.Target-selective delivery and activation of platinum-based anticancer agents.Current progress in nanotechnology applications for diagnosis and treatment of kidney diseases.Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents.Polymeric biomaterials for the delivery of platinum-based anticancer drugs.Exploiting developments in nanotechnology for the preferential delivery of platinum-based anti-cancer agents to tumours: targeting some of the hallmarks of cancer.Diruthenium(ii,iii) metallodrugs of ibuprofen and naproxen encapsulated in intravenously injectable polymer-lipid nanoparticles exhibit enhanced activity against breast and prostate cancer cells.Codelivery of Anti-cancer Agents via Double-walled Polymeric Microparticles/ Injectable Hydrogel: A Promising Approach for Treatment of Triple Negative Breast Cancer.Facile electrospinning of an efficient drug delivery system.Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.Platinum-based drugs: past, present and future.Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment.Anti prostate cancer using PEGylated bombesin containing, cabazitaxel loading nano-sized drug delivery system.3-octadecylcarbamoylacrylic acid-cisplatin nanocomplexes for the development of novel liposome formulation.Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.Effect of cisplatin containing liposomes formulated by unsaturated chain-containing lipids on gynecological tumor cells.Multifunctional platinum-based nanoparticles for biomedical applications.Human Serum Albumin Conjugated Nanoparticles for pH and Redox-Responsive Delivery of a Prodrug of Cisplatin.Overcoming tumor resistance to cisplatin through micelle-mediated combination chemotherapy.Oxaliplatin analogues with carboxy derivatives of boldine with enhanced antioxidant activityAntitumor properties of platinum(iv) prodrug-loaded silk fibroin nanoparticles.Surface functionalization of polymeric nanoparticles for tumor drug delivery: approaches and challenges.Magnetically Targeted Nanocapsules for PAA-Cisplatin-Conjugated Cores in PVA/SPIO Shells via Surfactant-Free Emulsion for Reduced Nephrotoxicity and Enhanced Lung Cancer Therapy.
P2860
Q26780494-6B7F8B51-DE96-4AA7-929E-A22DAE9AD740Q28066801-86ED2918-177A-46B7-9AB6-CCDB406A9488Q28396437-09915285-EF18-4109-AC2B-C5BCD3A6FC66Q30366990-A14DDF5E-4CD7-4FC7-A506-877F5B63CCD2Q33688875-E9A666A4-4DB2-450B-ABC2-9FE80F67D119Q34617008-C1CE772C-D0C1-4962-85F3-352F6EC7CF7FQ35032561-72487CBC-39C5-4A11-A1E6-EDE9E7B57EE1Q35116954-91261198-92BA-46C8-B886-E07A548ABB92Q35602780-78FC955D-A890-4E7D-B681-07D59782027BQ35679127-59900809-3A62-4063-A524-7183432C2210Q35812462-BD973EBC-3639-46C1-8B47-95942F01F01FQ35930103-0F498B8A-383D-47F3-A2CB-353629C1F324Q35978870-4EF366AB-A7BF-40BA-91EA-A6B677AA7F15Q35993977-729E58BF-94F4-4796-8B0C-E672AAC9E5B1Q36948510-7BB25775-84CA-4168-A393-2469F2F36B5AQ38198993-59AE63D9-9B38-458B-9C07-DAFC6F33417FQ38266485-35410E34-8B53-41BB-8A1D-3509AD92DA37Q38366771-FE7B8BD9-0DF6-46B5-A49A-217E2B0FBAC5Q38523600-A63C6D03-F72C-4076-BBDE-A82BBD346077Q38539866-6D5D26CA-AE37-45F4-BE8C-D07A0A09848BQ38546964-FB9EB095-0FFA-4A39-99B6-F01CBA352527Q38556758-7027C4FC-6C91-4255-8FD0-104C677CC3F9Q38633157-8B6FC572-4607-4EEC-A95D-A80DF4F6AC5AQ38662609-8FDD9916-43DD-4707-A6A8-340063ED8B07Q38694338-79512419-E2F0-46B5-890C-E0AC2DFE1294Q38703535-C9D1C24F-8928-4965-A6A9-F1B580B7763BQ38734711-EBE474A5-2A4C-4D69-B56C-CE3B7592EC9BQ38737115-533DB0FC-2986-4D6F-B5D7-E3BD3DF9E877Q38741016-D1B46C15-2404-46E3-95A7-8F5B774E36C4Q38773368-6E37054D-32C2-4158-808F-793BFB560D81Q38782365-2275CA52-DAC0-4ACF-AB9B-4EF0B34D3984Q38788994-DE2BBFE7-F19B-4DA1-BDB1-F6F0A965D45EQ38796115-BC0E26D3-B958-48D6-A84F-EA583A4099B0Q38812240-95A78025-0265-4B7A-8EB2-D74C60F859E1Q38832616-8E94EFA2-2E6D-438B-B065-9F5E9DC83A23Q38848959-194F9355-2DB7-4E7A-8399-D3025205315DQ38894400-33446F7D-FBB7-4664-9052-92CDEF10B016Q38896341-6DC582A0-BAB1-4F12-8D66-3E42B1A5CBD7Q38899902-16C53204-A22B-4D92-A60D-DFECF25D96E4Q38912446-22FEAC5C-BCDA-485E-BAE7-A7FD8E6A6B7A
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Nanocarriers for delivery of platinum anticancer drugs.
@ast
Nanocarriers for delivery of platinum anticancer drugs.
@en
Nanocarriers for delivery of platinum anticancer drugs.
@nl
type
label
Nanocarriers for delivery of platinum anticancer drugs.
@ast
Nanocarriers for delivery of platinum anticancer drugs.
@en
Nanocarriers for delivery of platinum anticancer drugs.
@nl
prefLabel
Nanocarriers for delivery of platinum anticancer drugs.
@ast
Nanocarriers for delivery of platinum anticancer drugs.
@en
Nanocarriers for delivery of platinum anticancer drugs.
@nl
P2860
P1476
Nanocarriers for delivery of platinum anticancer drugs
@en
P2093
Hardeep S Oberoi
Tatiana K Bronich
P2860
P304
P356
10.1016/J.ADDR.2013.09.014
P407
P577
2013-10-08T00:00:00Z